S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
5 Stocks to Buy Immediately (Ad)pixel
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
5 Stocks to Buy Immediately (Ad)pixel
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
5 Stocks to Buy Immediately (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Can Frontline Maintain This Momentum?
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
5 Stocks to Buy Immediately (Ad)pixel
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
5 Stocks to Buy Immediately (Ad)pixel
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
5 Stocks to Buy Immediately (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Can Frontline Maintain This Momentum?
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
5 Stocks to Buy Immediately (Ad)pixel
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
5 Stocks to Buy Immediately (Ad)pixel
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
5 Stocks to Buy Immediately (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Can Frontline Maintain This Momentum?
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
5 Stocks to Buy Immediately (Ad)pixel
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
5 Stocks to Buy Immediately (Ad)pixel
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
5 Stocks to Buy Immediately (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Can Frontline Maintain This Momentum?
NASDAQ:SUPN

Supernus Pharmaceuticals - SUPN Earnings Date, Estimates & Call Transcripts

$36.23
-0.04 (-0.11%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$36.06
▼
$36.77
50-Day Range
$34.93
▼
$42.03
52-Week Range
$24.95
▼
$42.09
Volume
549,179 shs
Average Volume
472,539 shs
Market Capitalization
$1.97 billion
P/E Ratio
35.18
Dividend Yield
N/A
Price Target
$47.00

Earnings Summary

Upcoming
Earnings Date
May. 8Estimated
Actual EPS
(Feb. 28)
$0.43 Missed By -$0.30
Consensus EPS
(Feb. 28)
$0.73
Last Year's Q2 EPS
(4/13/2022)
$0.04
Read Call Transcript
Listen to Call
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

SUPN Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

SUPN Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Supernus Pharmaceuticals Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20232$0.12$0.35$0.24 
Q2 20232$0.32$0.42$0.37 
Q3 20232$0.32$0.41$0.37 
Q4 20232$0.16$0.59$0.38 
FY 20238$0.92$1.77 $1.35

SUPN Earnings Date and Information

Supernus Pharmaceuticals last posted its quarterly earnings data on February 28th, 2023. The specialty pharmaceutical company reported $0.43 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.73 by $0.30. The firm had revenue of $167.33 million for the quarter, compared to the consensus estimate of $180.38 million. Its revenue was up 5.2% on a year-over-year basis. Supernus Pharmaceuticals has generated $1.03 earnings per share over the last year ($1.03 diluted earnings per share) and currently has a price-to-earnings ratio of 35.2. Earnings for Supernus Pharmaceuticals are expected to grow by 145.45% in the coming year, from $0.66 to $1.62 per share. Supernus Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 8th, 2023 based off prior year's report dates.

Supernus Pharmaceuticals Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/8/2023
(Estimated)		        
2/28/2023Q4 2022$0.73$0.43($0.30)$0.43$180.38 million$167.33 million    
11/8/2022Q3 2022$0.32$0.03($0.29)$0.03$173.22 million$177.35 million
8/4/2022Q2 2022$0.30$0.14($0.16)$0.14$164.23 million$170.10 million      
5/9/2022Q1 2022$0.26$0.43+$0.17$0.43$150.47 million$152.50 million      
4/13/2022Q4 2021$0.04+$0.04$0.04$159.05 million  
11/3/20219/30/2021$0.21$0.40+$0.19$0.40$141.32 million$148.46 million    
8/4/20216/30/2021$0.17$0.43+$0.26$0.43$135.50 million$141.33 million      
5/5/20213/31/2021$0.26$0.11($0.15)$0.11$131.77 million$130.93 million  
2/25/202112/31/2020$0.57$0.57$0.57$145.52 million$143.56 million  
11/3/20209/30/2020$0.27$0.74+$0.47$0.74$130.76 million$155.10 million    
8/18/20206/30/2020$0.42$0.65+$0.23$0.65$126.70 million$126.73 million    
5/5/20203/31/2020$0.30$0.40+$0.10$0.40$84.01 million$94.98 million  
2/25/2020Q4 2019$0.57$0.62+$0.05$0.62$107.27 million$100.45 million    
11/5/2019Q3$0.59$0.54($0.05)$0.54$108.70 million$102.14 million    
8/6/2019Q2 2019$0.56$0.6070+$0.0470$0.61$109.67 million$104.70 million    
5/7/20193/31/2019$0.44$0.34($0.10)$0.34$102.26 million$85.50 million
2/26/2019Q4 2018$0.27$0.48+$0.21$0.48$105.36 million$113.50 million  
11/6/20189/30/2018$0.43$0.52+$0.09$0.52$100.75 million$102.99 million  
8/7/2018Q2 2018$0.43$0.57+$0.14$0.57$101.01 million$99.54 million
5/8/2018Q1 2018$0.33$0.49+$0.16$0.49$85.26 million$90.43 million
2/27/2018Q4 2017$0.26$0.44+$0.18$0.62$87.84 million$88.44 million
11/6/2017Q3 2017$0.27$0.29+$0.02$0.29$78.74 million$80.40 million
8/2/2017Q2 2017$0.24$0.32+$0.08$0.32$68.54 million$75.83 million  
5/9/2017Q1 2017$0.22$0.19($0.03)$0.19$57.91 million$57.58 million  
2/28/2017Q4 2016$0.24$0.26+$0.02$0.26$58.87 million$62.37 million
1/20/2017Q3 2016$0.37+$0.37($0.44)$56.23 million$56.81 million
8/2/2016Q2 2016$0.13$0.18+$0.05$0.18$49.67 million$50.40 million  
5/3/2016Q1 2016$0.08$0.08$0.08$45.33 million$43.00 million  
3/2/2016Q4 2015$0.06$0.14+$0.08$0.14$42.93 million$42.70 million  
11/3/2015Q3 2015$0.02$0.08+$0.06$0.08$37.93 million$38.60 million  
8/4/2015Q2 2015$0.02$0.03+$0.01$0.03$34.07 million$35.10 million  
5/5/2015Q1 2015$0.02$0.05+$0.03$0.08$29.16 million$28.13 million  
3/10/2015Q4 2014($0.05)$0.08+$0.13$0.06$26.37 million$30.80 million
11/11/2014Q3 2014$0.45($0.20)($0.65)($0.79)$43.10 million$52.50 million
8/11/2014Q2 2014($0.18)$0.06+$0.24$0.04$19.85 million$29.67 million
5/12/2014Q1 2014($0.44)($0.36)+$0.08($0.34)$9.94 million$9.00 million
3/12/2014Q4 2013($0.54)($0.39)+$0.15($0.13)$7.78 million$10.30 million
11/12/2013Q3 2013($0.66)($0.65)+$0.01($0.52)$2.54 million$1.26 million  
8/13/2013Q2 2013($0.67)($0.57)+$0.10($0.25)$0.91 million$0.28 million
5/13/2013Q1 2013($0.63)($0.60)+$0.03($0.60)$0.57 million$0.15 million
3/14/2013Q4 2012($0.73)($0.51)+$0.22($0.51)
11/7/2012Q312($0.62)($0.55)+$0.07
8/10/2012Q2 2012($0.48)($0.61)($0.13)($0.61)
6/7/2012Q1 2012($2.06)($6.05)($3.99)($6.05)












Supernus Pharmaceuticals Earnings - Frequently Asked Questions

When is Supernus Pharmaceuticals's earnings date?

Supernus Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 8th, 2023 based off last year's report dates. Learn more on SUPN's earnings history.

Did Supernus Pharmaceuticals beat their earnings estimates last quarter?

In the previous quarter, Supernus Pharmaceuticals (NASDAQ:SUPN) missed the analysts' consensus estimate of $0.73 by $0.30 with a reported earnings per share (EPS) of $0.43. Learn more on analysts' earnings estimate vs. SUPN's actual earnings.

How can I listen to Supernus Pharmaceuticals's earnings conference call?

The conference call for Supernus Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call

How can I read Supernus Pharmaceuticals's conference call transcript?

The conference call transcript for Supernus Pharmaceuticals's latest earnings report can be read online. Read Transcript

How much revenue does Supernus Pharmaceuticals generate each year?

Supernus Pharmaceuticals (NASDAQ:SUPN) has a recorded annual revenue of $667.24 million.

How much profit does Supernus Pharmaceuticals generate each year?

Supernus Pharmaceuticals (NASDAQ:SUPN) has a recorded net income of $60.71 million. SUPN has generated $1.03 earnings per share over the last four quarters.

What is Supernus Pharmaceuticals's price-to-earnings ratio?

Supernus Pharmaceuticals (NASDAQ:SUPN) has a trailing price-to-earnings ratio of 35.18 and a forward price-to-earnings ratio of 54.89.

What is Supernus Pharmaceuticals's EPS forecast for next year?

Supernus Pharmaceuticals's earnings are expected to grow from $0.66 per share to $1.62 per share in the next year, which is a 145.45% increase.

More Earnings Resources from MarketBeat

Earnings Tools:
Earnings By Country:
Latest Articles:
Upcoming Earnings:
This page (NASDAQ:SUPN) was last updated on 4/1/2023 by MarketBeat.com Staff